AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma.
Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.
The company is headquartered in Newtown, Pennsylvania.
Country | United States |
IPO Date | Jun 27, 2014 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 22 |
CEO | Dane Carl Andreeff |
Contact Details
Address: 642 Newtown Yardley Road Newtown, Pennsylvania United States | |
Website | https://heliusmedical.com |
Stock Details
Ticker Symbol | HSDT |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001610853 |
CUSIP Number | 42328V504 |
ISIN Number | US42328V8019 |
Employer ID | 36-4787690 |
SIC Code | 3845 |
Key Executives
Name | Position |
---|---|
Dane Carl Andreeff | President, Chief Executive Officer & Director |
Jeffrey S. Mathiesen CPA | Chief Financial Officer, Treasurer, Secretary & Director |
Dr. Antonella Favit-Van Pelt M.D., Ph.D. | Chief Medical Officer |
Lawrence Picciano | Senior Vice President of Engineering, Quality & Regulatory Affairs |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 23, 2024 | 8-K | Current Report |
Nov 18, 2024 | 8-K | Current Report |
Nov 12, 2024 | 10-Q | Quarterly Report |
Nov 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Aug 12, 2024 | 10-Q | Quarterly Report |
Aug 12, 2024 | 8-K | Current Report |
Aug 09, 2024 | 8-K | Current Report |
Jul 24, 2024 | S-8 | Filing |
Jul 05, 2024 | 4 | Filing |
Jul 05, 2024 | 4 | Filing |